With the death of Pope Francis, the world loses not only a church leader but also a moral compass
Latest editorial
Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
An electron micrograph of HIV-1 virus particles (colourized red) replicating from an HIV-infected H9 T-cell (blue)
LYNNE WALSH previews the Bristol Radical History Conference this weekend
Keir Starmer’s £120 million to Sudan cannot cover the government’s complicity in the RSF genocide or atone for the long shadow of British colonialism and imperialism, writes CLAUDIA WEBBE
Join the traditional march from Clerkenwell Green, which will bring together countless international workers’ organisations in a statement against the far right
Ecuador’s election wasn’t free — and its people will pay the price under President Noboa
Mountains of research show that hardcore material harms children, yet there are still no simple measures in place
We face austerity, privatisation, and toxic influence. But we are growing, and cannot be beaten
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
Labour’s controversial plan to put the overweight and unemployed on the ‘skinny jab’ Mounjaro should set alarm bells ringing once we look into some of the research into the drug and the company set to supply it, warns CLAUDIA WEBBE
